Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG: Crizanlizuamb
DRUG: Standard of Care

Sponsor

Novartis Pharmaceuticals